Companies › Adneuris Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other, Psychiatry; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cebranopadol Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist | OPRL1, OPRK1, OPRD1, OPRM1 | Phase 3 | Pain; Chronic Pain | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07845071 | Cebranopadol | Phase 3 | Pain | Other | Jan 2027 |
| NCT07874620 | Cebranopadol | Phase 2 | Chronic Pain | Psychiatry | Mar 2027 |
AgelessRx Alkermes Syndeio Biosciences Axsome Therapeutics Trevi Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.